Form 4: Verrica Pharmaceuticals Director Acquires 20,000 Stock Options
SEC Form 4 Filing
Director Craig Ballaron acquired 20,000 stock options in Verrica Pharmaceuticals Inc. on June 6, 2024, according to a Form 4 filing.
Summary
- Craig Ballaron, a director of Verrica Pharmaceuticals Inc., acquired 20,000 stock options on June 6, 2024.
- The options have an exercise price of $8.78.
- The options vest in 12 equal monthly installments starting July 6, 2024, and will be fully vested by the date of the next annual meeting of stockholders, contingent upon continued service as a director.
- Following the transaction, Ballaron directly owns 20,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and principal stockholders) of a company buy or sell the company's securities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Craig Ballaron acquired 20,000 stock options. |
| 07/06/2024 | Vesting of stock options begins in 12 equal monthly installments. |
| 06/05/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.